The management of the diabetic patient with prior cardiovascular events

Reviews in Cardiovascular Medicine

Volumn 4, Issue SUPPL. 6, 2003, Pages

  Fonarow, Gregg C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blockade; Angiotensin converting enzyme inhibition; Cardiovascular events; Diabetes; Heart failure; Neurohormonal activation

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; ANGIOTENSIN ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; BISOPROLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; HEMOGLOBIN A1C; INSULIN; METFORMIN; METOPROLOL; NEUROHORMONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PLACEBO; RAMIPRIL; SPIRONOLACTONE; SULFONYLUREA DERIVATIVE; XAMOTEROL;

ACUTE DISEASE; AWARENESS; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG UTILIZATION; DYSLIPIDEMIA; ENZYME INHIBITION; FLUID RETENTION; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERINSULINEMIA; HYPERKALEMIA; HYPOGLYCEMIA; INCIDENCE; INSULIN SENSITIVITY; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PATIENT CARE; PHYSICIAN; PRESCRIPTION; PREVALENCE; RECEPTOR BLOCKING; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STANDARDIZATION; TREATMENT PLANNING; UNITED STATES;

ADRENERGIC AGENTS; ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; COMORBIDITY; DIABETES COMPLICATIONS; DIABETES MELLITUS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERGLYCEMIA; PREVALENCE; RECEPTORS, ALDOSTERONE; RISK FACTORS; UNITED STATES;

EID: 0347532618     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
2. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
3. American Heart Association. Heart Disease and Stroke Statistics - 2003 Update. Dallas, TX. American Heart Association; 2002.
4. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035-2038.
5. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996; 334:374-381.
6. Richards AM, Nicholls MG, Troughton RW, et al. Antecedent hypertension and heart failure after myocardial infarction. J Am Coll Cardiol. 2002;39:1182-1188.
7. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570-2581.
8. Chae C, Glynn R, Manson J. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999; 22:233-240.
9. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001;103:2668-2673.
10. Tenenbaum A, Motro M, Fisman EZ, et al. Functional class in patients with heart failure is associated with the development of diabetes. Am J Med. 2003;114:271-275.
11. Shindler DM, Kostis JB, Yusuf S, el al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am J Cardiol. 1996;77:1017-1020.
12. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001;24:1614-1619.
13. Dries DL, Sweitzer NK, Drazner MH, et al. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol. 2001:38:421-428.
14. Mosterd A, Cost B, Hoes AW, et al. The prognosis of heart failure in the general population: The Rotterdam Study. Eur Heart J. 2001;22:1318-1327.
15. Croft JB, Giles WH, Pollard RA, et al. Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med. 1999;159:505-510.
16. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248-254.
17. Cody RJ. The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease. Am J Cardiol. 1997;80:9J-14J.
18. Gavras I, Gavras H. Angiotensin II as a cardiovascular risk factor. J Hum Hypertens. 2002;16 (suppl 2):S2-S6.
19. Palatini P. Sympathetic overactivity in hypertension: a risk factor for cardiovascular disease. Curr Hypertens Rep. 2001;3 (suppl 1):S3-S9.
20. Tansey MJ, Opie LH. Relation between plasma free fatty acids and arrhythmias within the first twelve hours of acute myocardial infarction. Lancet. 1983;2(8347):419-422.
21. Festa A, D'Agostino R Jr, Hales CN, et al. Heart rate in relation to insulin sensitivity and insulin secretion in nondiabetic subjects. Diabetes Care. 2000;23:624-628.
22. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
23. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
24. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273:1450-1456.
25. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol. 2003;41:1529-1538.
26. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
27. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
28. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
29. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730-1737.
30. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-1390.
31. Jonas M, Reicher-Reiss H, Boyko V, et al. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group. Am J Cardiol. 1996;77:1273-1277.
32. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
33. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355.
34. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
35. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
36. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-1667.
37. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet. 1990;336:1-6.
38. Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J. 2001;141:899-907.
39. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7-13.
40. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens. 1998;11:1258-1265.
41. Jacob S, Rett K, Wicklmayr M, et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens. 1996;14:489-494.
42. Agrawal B, Wolf K, Berger A, Luft FC. Effect of antihypertensive treatment on qualitative estimates of microalbuminuria. J Hum Hypertens. 1996;10:551-555.
43. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
44. Knatterud GL, Klimt CR, Levin ME, et al. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: VII. Mortality and selected nonfatal events with insulin treatment. JAMA. 1978;240:37-42.
45. Wang CH, Weisel RD, Liu PP, et al. Glitazones and heart failure: critical appraisal for the clinician. Circulation. 2003;107:1350-1354.
46. Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med. 1997;102:99-110.